This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Neutral on Honeywell Aerospace; Outperform on M&T Bank and SailPoint; Buy on Ambiq Micro; Overweight on Abbott.
Stocks · News reference
Wall Street analysts revised targets: upgrades for NetApp and Humana; downgrades for PJT Partners; mixed target changes for Redwood, Marvell, Yum and S&P
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analysts initiated coverage: Neutral on Honeywell Aerospace; Outperform on M&T Bank and SailPoint; Buy on Ambiq Micro; Overweight on Abbott.
Barclays analyst Matt Miksic initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweight rating and announces Price Target of $120.
The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.
Cantor Fitzgerald analyst Ryan Tunis maintains Chubb (NYSE:CB) with a Neutral and raises the price target from $330 to $333.
Morgan Stanley analyst Bob Huang maintains Chubb (NYSE:CB) with a Equal-Weight and lowers the price target from $360 to $350.
CNBC Final Trades: Brown picks Snowflake, Baruch chooses Micron after strong earnings, Sethi selects Morgan Stanley, and Ethridge names Chubb.